Swedish Orphan Biovitrum (Sobi) and Oriola begin cooperation in Finland on 1 January 2017. Oriola will be in charge of warehousing and distribution of Sobi's pharmaceutical products and offer Sobi a broad selection of various expert services.Oriola and Sobi have collaborated in Sweden since 1997.
Sobi is an international speciality healthcare company dedicated to rare diseases. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. The product portfolio is primarily focused on haemophilia, inflammation and genetic diseases. Sobi also markets other speciality and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies.
“Sobi has been cooperating with Oriola in Sweden for many years. We want to utilise the experience and synergy benefits that we have gained through our cooperation and to further develop the distribution of our services and products with our new partner in Finland. Sobi is expecting Oriola to provide genuine partnership, efficient and high-quality distribution and innovativeness to develop operations also in the future,” says Vesa Loponen, Sobi's Managing Director.
“Oriola and Sobi have been engaged in successful cooperation in Sweden for a long time. At Oriola we are very pleased that Sobi has selected us as its partner also in Finland. Sobi plays an important role in the treatment of rare diseases, and we wish to contribute to their success. We are anticipating close and rewarding cooperation with them,” says Annastiina Palmroth-Holst, Services Business Unit Director at Oriola.
Business Unit Director, Services
tel. +358 (0)10 429 3405
Swedish Orphan Biovitrum
tel. +358 (0)201 558 847
Oriola provides services for healthcare actors who want to succeed in the Nordic and Baltic countries. Oriola focuses on long-term customer relationships and a wide service offering covering pharmaceutical distribution, branded products and other expert services. Oriola is part of the Finnish Oriola-KD Group. Oriola-KD provides pharmaceutical companies effective access to markets and improves consumers' wellbeing by ensuring that pharmaceuticals, health products and services are delivered in a safe and customer-friendly manner. Oriola-KD’s net sales for continuing operations in 2015 were approximately EUR 1.6 billion. The company has approximately 2,350 employees. Oriola-KD is listed on NASDAQ OMX Helsinki. For more information, visitwww.oriola-kd.com.
About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum (Sobi) is an international speciality healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on haemophilia, inflammation and genetic diseases. We also market a portfolio of speciality and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies.
Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and approximately 700 employees. The share (STO:SOBI) is listed on NASDAQ OMX Stockholm. For more information, visit www.sobi.com.